ISF 35

Drug Profile

ISF 35

Alternative Names: Ad-CD154; Ad-ISF35; Ad-ISF35 transduced CLL B-cells; Adenovirus-CD 154; Immune Stimulatory Factor 35; ISF-35

Latest Information Update: 26 Nov 2015

Price : $50

At a glance

  • Originator Memgen LLC
  • Developer Memgen; The Leukemia & Lymphoma Society; University of California, San Diego; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Gene therapies
  • Mechanism of Action CD40 ligand stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malignant melanoma
  • No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 18 Nov 2015 Preclinical trials in Malignant melanoma (Refractory metastatic disease) in USA (Intratumoural)
  • 18 Nov 2015 Memgen has worldwide patent protection for ISF 35
  • 18 Nov 2015 Preclinical data in Melanoma released by Memgen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top